Capsugel

Enteric capsules are widely used to protect acid‑sensitive compounds and to delay drug release until intestinal entry. However, evidence supporting...

Abstract The dynamic and transitory nature of the distal small intestine makes targeted drug delivery to this region particularly challenging....

Abstract Background/Objectives: Cholera remains an important global health problem. Inactivated oral cholera vaccines (OCVs) are essential in the WHO/GTFCC (World...

Capsugel®/ Lonza published a new podcast episode: For years, oral delivery of biologics has been viewed as impractical. But what...

Capsugel® Enprotect® capsule enables enteric delivery without the need for a post-filling coating step. This helps protect your sensitive active...

Abstract Biomacromolecules including peptides, proteins, antibodies, and gene medicines, comprise important classes of therapeutics in treating disease. A drawback of...

PRESS RELEASE Basel, Switzerland, 28 May 2026 – Lonza Capsugel has released new peer reviewed research showing that its Licaps® DUOCAP®...

Abstract Background: Rebamipide (REB) is a poorly water-soluble drug with limited ocular bioavailability, necessitating advanced delivery strategies for sustained therapy in...

Abstract Oral delivery of peptides represents a promising alternative to invasive injectable therapies, offering improved patient adherence and convenience. Glucagon-like...

This poster has been presented at the 15th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, which took place in...